...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Two big thank you’s

tada, I think it's time for management to give ZEN-3694 a name, the same way RVX-208 is now called apabetalone!

 

Koo

Share
New Message
Please login to post a reply